Freda C. Lewis-Hall

CIK: 0001437909

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)8 (88.9%)

Compensation grants

Other (G, F, J, C, D, …)1 (11.1%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

HELP

Helus Pharma Inc.

Director

PYXS

Pyxis Oncology, Inc.

Director

CDT

CONDUIT PHARMACEUTICALS INC.

Director

SWTX

SpringWorks Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (9 total)

PYXS
Pyxis Oncology, Inc.
Mar 24, 2026
Award(A)
Stock Option (Right to Buy)
Direct
45.9K shares-
CDT
CDT Equity Inc.
Aug 12, 2025
Award(A)
Direct
35K shares-
CDT
CDT Equity Inc.
Aug 5, 2025
Award(A)
Stock Option (Right to Buy)
Direct
15K shares-
SWTX
SpringWorks Therapeutics, Inc.
Jul 1, 2025
Disposition(D)
Direct
24.7K shares-
SWTX
SpringWorks Therapeutics, Inc.
May 14, 2025
Award(A)
Direct
10.1K shares-
PYXS
Pyxis Oncology, Inc.
Mar 31, 2025
Award(A)
Stock Option (Right to Buy)
Direct
37K shares at avg. $0.98-
CDT
CONDUIT PHARMACEUTICALS INC.
Mar 30, 2025
Award(A)
Direct
47.6K shares at avg. $0.89$42K
CDT
CONDUIT PHARMACEUTICALS INC.
Dec 18, 2024
Award(A)
Stock Option (Right to Buy)
Direct
420K shares at avg. $0.07-
CDT
CONDUIT PHARMACEUTICALS INC.
Nov 18, 2024
Award(A)
Direct
438K shares at avg. $0.09$40K

		Type	Shares	Price		Ownership
Mar 24, 2026	PYXS Pyxis Oncology, Inc.	Award(A) Stock Option (Right to Buy)	45,867	-	-	Direct
Aug 12, 2025	CDT CDT Equity Inc.	Award(A)	35,000	-	-	Direct
Aug 5, 2025	CDT CDT Equity Inc.	Award(A) Stock Option (Right to Buy)	15,000	-	-	Direct
Jul 1, 2025	SWTX SpringWorks Therapeutics, Inc.	Disposition(D)	24,727	-	-	Direct
May 14, 2025	SWTX SpringWorks Therapeutics, Inc.	Award(A)	10,060	-	-	Direct
Mar 31, 2025	PYXS Pyxis Oncology, Inc.	Award(A) Stock Option (Right to Buy)	36,979	$0.98	-	Direct
Mar 30, 2025	CDT CONDUIT PHARMACEUTICALS INC.	Award(A)	47,612	$0.89	$42,375	Direct
Dec 18, 2024	CDT CONDUIT PHARMACEUTICALS INC.	Award(A) Stock Option (Right to Buy)	420,000	$0.07	-	Direct
Nov 18, 2024	CDT CONDUIT PHARMACEUTICALS INC.	Award(A)	437,976	$0.09	$40,250	Direct

1-9 of 9 transactions

About Lewis-Hall Freda C

Lewis-Hall Freda C (SEC CIK 0001437909) files insider reports with the SEC as Director of Helus Pharma Inc. (HELP), Director of Pyxis Oncology, Inc. (PYXS) and Director of CONDUIT PHARMACEUTICALS INC. (CDT). Signal8 also holds filings tied to 1 other company.

Signal8 holds 9 ownership filings by Lewis-Hall Freda C (1 Form 3, 8 Form 4), filed between Nov 20, 2024 and Oct 26, 2026. Those filings report 9 transactions, from Nov 18, 2024 to Mar 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lewis-Hall Freda C's filings is in TORONTO.

Recent filings by Lewis-Hall Freda C

Mar 24, 2026: Grant or award of PYXS derivative securities (Form 4, code A).
Aug 12, 2025: Grant or award of CDT shares (Form 4, code A).
Aug 5, 2025: Grant or award of CDT derivative securities (Form 4, code A).
Jul 1, 2025: Disposition to issuer transaction of SWTX shares (Form 4, code D).
May 14, 2025: Grant or award of SWTX shares (Form 4, code A).

Other insiders filing for Helus Pharma Inc. (HELP)

Durgam Suresh K., Director
Inamdar Amir, Director
Froese Grant, Director
Hoskins Eric, Director
Lawson Mark, Director
Firestone Theresa, Director

How to read Form 4 transaction codes